Klin Farmakol Farm. 2025;39(4):241-244 | DOI: 10.36290/far.2025.043

Dapagliflozin in the treatment of IgA nephropathy in a paediatric patient

Markéta Ručková1, 2, Petra Matalová3
1 Dětské lékařství, Městská nemocnice Ostrava
2 Klinika dětského lékařství, Fakultní nemocnice Ostrava
3 Ústav farmakologie LF UP a FN Olomouc

IgA nephropathy is the most common primary chronic glomerulonephritis in children and adults. It manifests itself as haematuria and proteinuria. Given that approximately half of patients develop kidney failure after 20 years, the prognosis is serious. In recent years, new treatment options have emerged for adults, including SGLT2 inhibitors, endothelin receptor antagonists, and targeted-release budesonide. These drugs are not yet approved for use in children with IgA nephropathy, but SGLT2 inhibitors are approved for children with diabetes mellitus type 2 (T2DM) over the age of 10. We describe the case of a boy with IgA nephropathy and an inadequate response to corticosteroids, in whom treatment with dapagliflozin had a positive effect on proteinuria and may improve his prognosis in the long term.

Keywords: IgA nephropathy, dapagliflozin, prednisone, renal biopsy.

Received: July 4, 2025; Revised: July 14, 2025; Accepted: July 14, 2025; Published: December 22, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ručková M, Matalová P. Dapagliflozin in the treatment of IgA nephropathy in a paediatric patient. Klin Farmakol Farm. 2025;39(4):241-244. doi: 10.36290/far.2025.043.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Coppo R, Amore A. IgA nephropathy. In: Geary D, Schaefer F, editors. Pediatric Kidney Disease. Springer; 2016. p. 515-527. Go to original source...
    2. Maixnerová D. Budesonid s cíleným uvolňováním v terminálním ileu v léčbě IgA nefropatie [Internet]. Lékařství vinohrady; 2024 [cited 2025 Jul 2]. Available from: https://www.lekarvinohrady.cz/publikace/.
    3. Vondrák K, Skálová S, Šuláková T, et al. Glomerulopatie. In: Janda J, Seeman T, editors. Dětská nefrologie. Grada; 2021. p. 287-335.
    4. Ryšavá R. Oxfordská klasifikace - krok ke sjednocení diagnostiky a zlepšení odhadu prognózy IgA nefropatie. Postgrad Nefrol. 2009;7(5):71-72.
    5. KDIGO 2024 Clinical practice guideline for the management of immunoglobulin A nephropathy (IgAN) and immunoglobulin A vasculitis (IgAV) [Internet]. KDIGO; 2024 [cited 2025 Jul 14]. Available from: https://kdigo.org/wp-content/uploads/2024/08/KDIGO-2024-IgAN-IgAV-Guideline-Public-Review-Draft.pdf.
    6. The international IgA nephropathy (IgAN) prediction tool [Internet]. MDCalc; [cited 2025 Jul 2]. Available from: https://www.mdcalc.com/calc/10533/international-iga-nephropathy-prediction-tool.
    7. Gross O, Haffner D, Schaefer F, et al. SGLT2 inhibitors: approved for adults and cats but not for children with CKD. Nephrol Dial Transplant. 2024;39(6):907-909. Go to original source... Go to PubMed...
    8. Janda J, Dušek J, Seeman T. Vyšetření moči. In: Seeman T, Janda J, editors. Dětská nefrologie. Grada; 2021;41-57.

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.